These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16709987)

  • 21. Indian company seeks US approval for generic AIDS drugs.
    Nature; 2004 Aug; 430(7001):716. PubMed ID: 15306779
    [No Abstract]   [Full Text] [Related]  

  • 22. Essential AIDS medications in India.
    Thomas J
    Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
    [No Abstract]   [Full Text] [Related]  

  • 23. [Why patent-protected drugs' cost efficiency should be compared with generic preparations].
    Berggren F; Lundin D; Ramsberg J
    Lakartidningen; 2006 Jan 25-31; 103(4):223-4. PubMed ID: 16491555
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA grants tentative approval to first generic version of antiretroviral Viread.
    AIDS Patient Care STDS; 2008 Jan; 22(1):86. PubMed ID: 18453039
    [No Abstract]   [Full Text] [Related]  

  • 25. Competition body rules that drug companies "abused" their position.
    Sidley P
    BMJ; 2003 Oct; 327(7421):946. PubMed ID: 14576226
    [No Abstract]   [Full Text] [Related]  

  • 26. . . . and Brazilian AIDS programme threatened by US trade action.
    Int J Epidemiol; 2001 Apr; 30(2):413. PubMed ID: 11369751
    [No Abstract]   [Full Text] [Related]  

  • 27. Patent injustice: how India brought cheap HIV drugs to Africa.
    Menghaney L
    BMJ; 2013 Nov; 347():f7013. PubMed ID: 24277626
    [No Abstract]   [Full Text] [Related]  

  • 28. Generic and branded drugs for the treatment of people living with HIV/AIDS.
    Bartlett JA; Muro EP
    J Int Assoc Physicians AIDS Care (Chic); 2007 Mar; 6(1):15-23. PubMed ID: 17329500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indian company offers cheap anti-AIDS drugs.
    Dickson D
    Nature; 2001 Feb; 409(6822):751. PubMed ID: 11236967
    [No Abstract]   [Full Text] [Related]  

  • 30. HIV/AIDS: Latin America & Caribbean. Brazil: ten years after.
    Cohen J
    Science; 2006 Jul; 313(5786):484-7. PubMed ID: 16873654
    [No Abstract]   [Full Text] [Related]  

  • 31. Legal challenge to India's patent laws threatens access to generic drugs, says charity.
    Moszynski P
    BMJ; 2011 Sep; 343():d5753. PubMed ID: 21908529
    [No Abstract]   [Full Text] [Related]  

  • 32. Novartis faces growing pressure to drop patent case against Indian government.
    Hargreaves S
    BMJ; 2007 Feb; 334(7590):383. PubMed ID: 17322224
    [No Abstract]   [Full Text] [Related]  

  • 33. Amendments to the Canadian Patent Act to address drug access: is help on the way?
    Penner MD; Narayanan P
    Food Drug Law J; 2005; 60(3):459-70. PubMed ID: 16304751
    [No Abstract]   [Full Text] [Related]  

  • 34. Changes to India's patent law may deny cheap drugs to millions.
    Mudur G
    BMJ; 2005 Mar; 330(7493):692. PubMed ID: 15790640
    [No Abstract]   [Full Text] [Related]  

  • 35. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 36. Patents versus patients? Antiretroviral therapy in India.
    Havlir DV; Hammer SM
    N Engl J Med; 2005 Aug; 353(8):749-51. PubMed ID: 16120852
    [No Abstract]   [Full Text] [Related]  

  • 37. Indian generic drug production. Benefits of EU-India free trade agreement.
    Ager B
    BMJ; 2011 Apr; 342():d2439. PubMed ID: 21502277
    [No Abstract]   [Full Text] [Related]  

  • 38. Taking TRIPS to India--Novartis, patent law, and access to medicines.
    Mueller JM
    N Engl J Med; 2007 Feb; 356(6):541-3. PubMed ID: 17287473
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug costs threaten patent protection.
    Cimons M
    Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.